Tag: action

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Apple Inc. (“Apple” or the “Company”) (NASDAQ: AAPL).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit is pending against Rocket Companies, Inc. (“Rocket Companies” or the “Company”) (NYSE: RKT). Investors in Rocket Companies securities are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Data featured in oral presentation and poster session at 48^th European Cystic Fibrosis Conference

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NASDAQ: TMCI).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Bitfarms Ltd. ("Bitfarms" or the "Company") (NASDAQ: BITF) and certain officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 25-cv-02630, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Bitfarms securities between March 21, 2023 and December 9, 2024, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

PRINCETON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today spotlights the efforts of Ellen Kim, M.D., Lead Principal Investigator for the Company’s Phase 3 FLASH (1 and 2) studies in early stage cutaneous T-cell lymphoma (CTCL), in advancing HyBryte™ (synthetic hypericin) as a potential new therapy for patients living with mycosis fungoides (MF), the most common form of CTCL.